Advertisement

Topics

Newron Pharmaceuticals SpA Company Profile

22:23 EDT 22nd June 2018 | BioPortfolio

Newron Pharmaceuticals SpA is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule drugs for the treatment of central nervous system (CNS) diseases. Our clinical focus is on Parkinson's disease and pain. We were established in 1999 as a spin-off from Pharmacia & Upjohn and are headquartered in Bresso, near Milan, Italy. We are conducting Phase III clinical trials with safinamide, a molecule with multiple mechanisms of action for the treatment of Parkinson’s disease and Phase II trials for Restless Leg Syndrome. Phase II clinical trials with ralfinamide, an innovative treatment for neuropathic pain, are on-going. Newron’s clinical pipeline is supported by a broad portfolio of early stage proprietary compounds generated by our ion channel drug discovery platform or in-licensed. We maintain a broad portfolio of discovery and development programs which enables to diversify risk and utilize our development capacity fully.

Location

via Ludovico Ariosto 21
Bresso
Milano
20091
Italy

Contact

Phone: 39 02 610 3461
Fax: 39 02 610 34654
Email: info@ newron.com


News Articles [499 Associated News Articles listed on BioPortfolio]

DGAP-News: Newron Pharmaceuticals S.p.A.: Veränderung im Verwaltungsrat (deutsch)

Newron Pharmaceuticals S.p.A.: Veränderung im Verwaltungsrat DGAP-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Personalie Newron Pharmaceuticals S.p.A.: Veränderung im Verwaltungsrat 08.02.....

DGAP-News: Newron Pharmaceuticals S.p.A.: Newron unterstützt den internationalen Rare Disease Day(R) 2018 sowie Studien zum Rett-Syndrom (deutsch)

Newron Pharmaceuticals S.p.A.: Newron unterstützt den internationalen Rare Disease Day(R) 2018 sowie Studien zum Rett-Syndrom DGAP-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Sonstiges Ne...

Newron Pharmaceuticals (NWRN) - 2018 focus on the CNS pipeline

Edison Investment Research - Pharmaceutical & healthcare - Newron Pharmaceuticals: Xadago for Parkinson’s disease (PD) is now available in 14 European countries through partner, Zambon. Addition...

Newron: Bo Jesper Hansen tritt zur GV aus Verwaltungsrat zurück

Zürich (awp) - Bei Newron Pharmaceuticals kommt es zu Veränderungen im Verwaltungsrat. Bo Jesper Hansen wird mit Wirkung ab der nächsten Generalversammlung am 27. März 2018, als Nicht-exekutives M...

Newron Pharmaceuticals-Aktie: Erwartungsgemäße Ergebnise 2017, aber noch ungeklärte Fragen

Zürich - Newron Pharmaceuticals-Aktienanalyse von Aktienanalyst Stefan Schneider von Vontobel Research: Stefan Schneider, Aktienanalyst von Vontobel Research, rät in einer aktuellen Aktienanalyse d....

Newron Pharmaceuticals-Aktie: Erwartungen für Xadago in USA/EU weiter gesenkt

Zürich - Newron Pharmaceuticals-Aktienanalyse von Aktienanalyst Stefan Schneider von Vontobel Research: Stefan Schneider, Aktienanalyst von Vontobel Research, senkt in einer aktuellen Aktienanalyse.....

Newron Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the centr...

Newron Pharmaceuticals to Present at the UBS Global Healthcare Conference 2018

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the centr...

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [133 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause ...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines and Pharmaceuticals.

Methods to incorporate deuterium and tritium atoms into organic molecules are valuable for medicinal chemistry. The prevalence of pyridines and diazines in pharmaceuticals means that new ways to label...

Environmental concentrations of pharmaceuticals directly affect phytoplankton and effects propagate through trophic interactions.

Pharmaceuticals are found in freshwater ecosystems where even low concentrations in the range of ng Lmay affect aquatic organisms. In the current study, we investigated the effects of chronic exposure...

Clinical Trials [216 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1322 Associated Companies listed on BioPortfolio]

Newron Pharmaceuticals S.p.A.

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Compan...

Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule drugs for the treatment of central nervous system (CNS) diseases. Ou...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Newron Pharmaceuticals SpA" on BioPortfolio

We have published hundreds of Newron Pharmaceuticals SpA news stories on BioPortfolio along with dozens of Newron Pharmaceuticals SpA Clinical Trials and PubMed Articles about Newron Pharmaceuticals SpA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Newron Pharmaceuticals SpA Companies in our database. You can also find out about relevant Newron Pharmaceuticals SpA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Corporate Database Quicklinks



Searches Linking to this Company Record